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ABSTRACT 
 
B-Raf mutations are identified in 40-50% of patients with melanoma and among them, the substitution 
of valine for glutamic acid at position 600 (V600EB-Raf) is the most frequent. Treatment of these patients with B-
Raf inhibitors has been associated with a clear clinical benefit. Unfortunately, multiple resistance mechanisms 
have been identified and new potent and selective inhibitors are currently needed. In this work, five different 
type II inhibitors, which bind V600EB-Raf in its DFG-out conformation, have been studied using molecular 
dynamics, free energy calculations and energy decomposition analysis. The ranking of calculated MM-
PB/GBSA binding affinities is in good agreement with the experimentally measured ones. The per-residue 
decomposition of ΔGbinding, within the MM-GBSA approach, has been used to identify the key residues 
governing the allosteric binding of the studied compounds to the V600EB-Raf protein kinase. Results indicate that 
although van der Waals interactions are key determinants for binding, hydrogen bonds also play an important 
role. This work also provides a better structural understanding of the binding of DFG-out inhibitors to V600EB-
Raf, which can be used in a further step for rational design of a new class of B-Raf potent inhibitors. 
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1. INTRODUCTION 
 
 The mitogen-activated protein kinase signal transduction pathway (MAPK) regulates cell growth, 
proliferation and differentiation in response to growth factors, cytokines and hormones. Importantly, the gain or 
loss of function of key elements in this signaling pathway has been related with the appearance and development 
of many types of cancer. One of these key elements is the Ras activating factor (RAF) family of serine/threonine 
kinases, composed by the isoforms A-Raf, B-Raf and C-Raf, which with the downstream molecules MEK and 
ERK constitute the MAPK signaling pathway. Activation of B-Raf is produced by binding to Ras, whereas A- 
and C-Raf activation requires additional signaling. 
While mutations in A-Raf and C-Raf are rare in human cancer, mutations of B-Raf have been detected 
in many types of cancer such as thyroid, colorectal, ovarian or melanomas [1]. Among them, the substitution of 
valine for glutamic acid at position 600 in the activation segment, adjacent to the kinase conserved DFG motif 
(residues 594-596), accounts for 90% of B-Raf mutations in human cancers [2]. This mutation renders the kinase 
constitutively active, being 700-fold more active than the wild type [3] and independent of Ras function. 
Because of these findings, V600EB-Raf has emerged as an attractive target for cancer treatment. 
Two different conformational states have been characterized for B-Raf. In the active state, also known 
as DFG-in, residue D594 chelates the magnesium cation that interacts with the two phosphate groups of ATP. 
Rotation of this residue switches the enzyme to the inactive state, also called DFG-out and characterized by the 
orientation of F595 towards the ATP-binding site. This change in orientation of phenylalanine not only blocks 
the binding of the nucleotide to the enzyme [4], but also exposes an additional hydrophobic binding group 
adjacent to the ATP binding site, which is also known as allosteric site [5]. 
In recent years many efforts have been made to develop B-Raf inhibitors. These inhibitors can be 
classified into two different types [6]. Type I inhibitors recognize the active conformation of the kinase and act 
as ATP-competitive inhibitors, whereas type II B-Raf inhibitors stabilize the inactive conformation of the 
enzyme. 
Sorafenib (Nexavar), approved by the FDA for use in the treatment of advanced renal cell carcinoma 
(RCC) and hepatocellular carcinoma (HCC) [7] was the first V600EB-Raf inhibitor. This inhibitor stabilizes the 
enzyme in its DFG-out conformation. Unfortunately, this drug presented ineffective results in clinical trials for 
melanoma [8], which led to the emergence of a second-generation of inhibitors including Vemurafenib 
(PLX4032), Dabrafenib and LGX818, which in contrast to Sorafenib, binds to V600EB-Raf in its active or DFG-in 
conformation [9]. However, acquired resistance to B-Raf inhibitor treatment [10] points out the need for the 
development of new inhibitors [11].  
Structure-based drug design has emerged as an attractive and promising approach and has been 
successfully applied in many drug discovery projects [12, 13]. Different studies have been done describing the 
design of a novel series of V600EB-Raf inhibitors via structure-based methods [14-18]. But, to data, only few 
studies have been done applying this approach to the specific analysis of V600EB-Raf/ligand interactions. Mayor 
parts of them are centered in the pharmacophore and binding analysis of V600EB-Raf inhibitors acting basically in 
the DFG-in conformation [19-22]; other are mainly based in the docking and posterior analysis by molecular 
dynamics of some DFG-out inhibitors [23-26] or on a purely 3D-QSAR approach [27]. But, none of them make 
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a specific and deeper comparison of available experimental structures of V600EB-Raf/ligand systems in the DFG-
out conformation. 
Thus, this work is aimed at identifying the interactions that govern the binding of five different type II 
inhibitors to V600EB-Raf in its DFG-out conformation using molecular dynamics (MD), MM-PB/GBSA free 
energy calculations and MM-GBSA free energy decomposition analysis. Moreover, the availability of the 
corresponding experimental complexes in the Protein Data Bank avoids any bias introduced by an incorrect 
selection of docking poses, allowing us to identify the key structural features responsible for the binding to 
V600EB-Raf in its DFG-out conformation. This information can be used in a further step for rational design of a 
new class of potent inhibitors. 
2. MATERIALS AND COMPUTATIONAL METHODS 
 
 The ff99SB [28] and gaff [29] force fields, as implemented in the AMBER v.11 [30] suite of programs 
were used to model the protein and the ligands, respectively. Molecular simulations were carried out under 
periodic boundary conditions using the particle-mesh-Ewald method [31] for the treatment of the long-range 
electrostatic interactions. A cutoff distance of 10 Å was selected to compute the non-bonded interactions and the 
solvent was considered explicitly using TIP3P [32] water molecules with a minimum distance from the edge of 
the box of 15 Å and removing those water molecules closer than 1.8 Å from any atom. Counterions were added, 
when necessary, to neutralize the systems. 
To prepare the systems, analyze the root mean square fluctuation (rmsf), identify intermolecular 
hydrogen bonds, van der Waals and electrostatic interactions, obtain total binding free energies and analyze the 
contribution of each receptor residue to the total binding free energy for all the studied complexes during the 
production time, the Antechamber, LEaP, ptraj and MMPBSA.py modules of AmberTools12 package [30] were 
used. All figures were rendered with the Pymol graphics program [32]. 
  
2.1 Preparation of the complexes 
 
The chemical structures and the reported IC50 inhibitory values for the five DFG-out inhibitors studied 
in this work are shown in Figure 1. The atomic coordinates of the five complexes with V600EB-Raf were retrieved 
from the Protein Data Bank (PDB entries: 1UWJ [3], 3C4C [34], 3IDP [35], 3II5 [36], 3Q96 [237]). In the case 
of the 1UWJ and 3Q96 complexes, only one of the two asymmetrically packed kinase-inhibitor complexes of the 
crystallographic unit was selected for further studies. In the case of the 3C4C structure the DFG-out unit was 
selected. After removing water molecules and counterions, the missing residues of these structures, 
corresponding to a loop located in the vicinity of the kinase conserved DFG motif (from residues 596 to 613), 
were modeled using the MOE homology modelling module [38] and the primary sequence of wild type B-Raf 
protein with an introduced V600E mutation. For each complex, only the lowest energy model was considered for 
further studies. However, none of the studied complexes modeled through minimization and molecular dynamics 
(20 ns) reached the convergence expected for systems using as initial structure one coming from an x-ray 
experiment : An analysis of the MD trajectories using the VMD [39] program exposed an excessive freedom of 
the loop caused by the lack of secondary structure. In order to overcome this problem, new coordinates for the 
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missing loop were obtained from the coordinates of the equivalent residues of the c-Abl protein (PDB entry 1IEP 
[40] ), superposing the main atoms of the first and the last residues of the missing loop of both structures. Next, 
all five systems were prepared for subsequent calculations using the LEaP module of Amber v.11 as previously 
stated.  
 
2.2 Energy minimization 
 
The five complexes were energy minimized before molecular dynamics in order to remove possible 
steric clashes and adapt the systems to the force field using a four-step procedure. In the first step, the protein 
and the ligand were fixed and only water molecules and counterions were allowed to relax. In a second step, also 
the side chains were minimized, keeping the backbone and the ligand frozen. Next, only the backbone of the 
protein was kept frozen. Finally, the complexes were energy minimized until the final root mean square (rms) 
energy gradient was lower than 1 kcal/mol. 
 
2.3 Simulated annealing 
 
In order to obtain a better adaptation of the modeled loop to each particular complex, the structures 
obtained at the end of the four-step minimization procedure were subjected to one cycle of simulated annealing. 
During this procedure, all the atoms of the system, except those belonging to the modeled loop, were kept 
frozen. The annealing was carried out using a multi-step procedure: (1) the temperature of the system was 
increased to 300 K at a constant rate of 30 K/10 ps within the NVT ensemble; (2) at 300 K, the density of the 
system was equilibrated by carrying out 400 ps of simulation in the NPT ensemble; (3) then, 1 ns of simulation 
was performed within the NVT ensemble; (4) after this time, the temperature of the system was gradually 
decreased at a constant rate of 30 K / 10 ps; (5) finally, the system was energy minimized without any restriction 
for 5000 cycles of steepest descents. Then, the obtained minimized structures were used as starting point for the 
MD simulations. 
 
2.4 Molecular dynamics simulations 
 
 The minimized structures were gradually heated within the NVT ensemble from 0 to 300K during 200 
ps at a constant rate of 30 K / 20 ps using the Berendsen’s algorithm [41] with a time coupling constant of 0.2 ps. 
During the heating procedure, all the backbone atoms excluding those of the modeled loop were constrained to 
their initial positions using a force constant of 0.1 kcal /mol Å. The SHAKE algorithm was employed on all 
atoms covalently bonded to hydrogen atoms, allowing an integration time step of 2 fs. Finally, a MD production 
run within the NVT ensemble of 30 ns was performed for each system at a constant temperature of 300 K. The 
coordinates of the trajectories were saved every 2 ps throughout the simulation. Binding free energy and 
hydrogen bond analyses were performed for the last 5 ns of simulation using 500 snapshots. However, the 
convergence of the binding free energy was checked calculating these values for the whole MD, with MM-
PBSA and MM-GBSA, using this time 100 snapshots, extracted each 10 ps, for each ns of MD.  
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2.5 Binding Free energy calculations 
 
 Binding free energies (ΔGb) were calculated using the Molecular Mechanics Generalized Born Surface 
Area (MM-GBSA) and the Molecular Mechanics Poisson-Boltzmann Surface Area (MM-PBSA) algorithms as 
implemented in AmberTools12. According to these approaches, the total binding free energy can be calculated 
using the equation: 
ΔGb = ΔHgas + ΔGsolv - TΔS  
where ΔHgas, the gas phase interaction energy, is calculated as the sum of the internal energy (ΔHint) and two 
non-bonded terms corresponding to the van der Waals (ΔHvdW) and electrostatic (ΔHelec) molecular mechanics 
energies: 
ΔHgas = ΔHint + ΔHvdW + ΔHelec  
The solvation free energy (ΔGsolv) is obtained by summing the polar (ΔGpolar) and nonpolar (ΔGnonpolar) 
terms: 
ΔGsolv= ΔGpolar + ΔGnonpolar 
The ΔGpolar can be calculated solving the Poisson-Boltzmann (PB) equation or using the Generalized 
Born (GB) method. In the present work, we used the Onufriev-Bashford-Case (OBC) generalized Born [42] 
(igb=5) as implemented in AmberTools12. The nonpolar contribution (ΔGnonpolar) is calculated from the solvent 
accessible surface area (SASA) according to the equation: 
ΔGnonpolar = γ SASA + β  
where the values for γ and β were set to 0.00542 kcal / mol Å2 and 0.9200 kcal /mol in the MM-PBSA [43] 
approach, and to 0.0072 kcal / mol Å2 and 0 kcal / mol in MM-GBSA [44]. Values for interior and exterior 
dielectric constants were set to 1 and 80, respectively.  
 The entropic contribution to the total binding free energy was computed within the harmonic entropy 
approximation using the normal mode analysis (NMA) implemented in Ambertools12. Because of the high 
computational requirements, the entropic contribution was averaged over 100 snapshots extracted at a time 
interval of 50 ps from the last 5 ns of each trajectory. 
 
2.6 Multiple molecular dynamics 
 
 For each one of the five different V600EB-Raf/inhibitor complexes studied in the present work, the MM-
PBSA and MM-GBSA binding free energies were alternatively calculated as averages over the binding free 
energy values obtained from ten different 10 ns molecular dynamics trajectories using as starting point the 
corresponding minimized structures. Binding free energy values for each one of these trajectories were 
calculated over the full trajectory, and also over the last 5 ns. In both cases, the energy values were averaged 
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over 100 snapshots extracted at a time interval of 10 ps from each ns of the analyzed trajectory. The entropic 
contributions obtained as described in section 2.5 were used here. 
 
2.7 Pairwise free energy decomposition  
 
The contribution of each V600EB-Raf protein residue to the total binding free energy of each complex was 
analyzed using the MM-GBSA decomposition protocol [45] implemented in the MMPBSA.py module of 
AmberTools12. The binding interaction for each residue–residue pair includes three terms: van der Waals 
contribution (ΔGvdw), electrostatic contribution (ΔGele) and solvation contribution (ΔGsolv). The polar 
contribution of ΔGsolv was computed as before using the generalized Born model based on the parameters 
developed by Onufriev et al [42]. All energy components were calculated using 500 snapshots corresponding to 
the last 5 ns of the full length molecular dynamics run. 
 
2.8 Analysis of the hydrogen bonds 
 
 The hydrogen bonds established between the different ligands and the V600EB-Raf protein were analyzed 
using the ptraj module of Ambertools12 over the last 5 ns of the MD. The parameters used to consider an 
interaction as a hydrogen bond were: (1) distance between the hydrogen acceptor and donor centers less than 3.5 
Å, and (2) acceptor-H-donor (θHB) angle equal or greater than 120°. Values for the hydrogen bond angles are 
reported as 180-θHB. The percentage of occupation quantifies the number of snapshots in which the conditions of 
distance and angle specified are satisfied.  
 
3. RESULTS AND DISCUSSION 
 
3.1 Convergence of the MD simulations 
 
In order to analyze the structural stability of the modeled systems, as well as the convergence of each 
MD simulation, the root mean square deviation (rmsd) of the Cα atomic positions was computed for each 
complex taking as reference the starting point for the MD simulations (Figure 2). However, prior to this analysis, 
the flexibility of each V600EB-Raf amino acid was checked by computing the Cα rmsf. Thus, those residues 
exhibiting the largest rmsf values, being therefore more flexible, were not considered for rmsd calculations. As 
expected, the maximum values of rmsf were obtained for those residues belonging to the modeled loop, being 
especially significant in the case of the 3II5 complex, which suggested us to extend the MD trajectory to 40 ns to 
ensure a reasonable degree of convergence. 
The rmsf values obtained for each protein residue, except for those belonging to the modelled loop, are 
very similar for all studied complexes. This observation suggests that these inhibitors show a similar binding 
mechanism. As concerns the ligands, those belonging to the 1UWJ, 3C4C and 3IDP crystallographic complexes 
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show the lower mobilities (rmsd < 1 Å), whereas the 3II5 and 3Q96 crystallographic ligands show higher 
flexibility, although their rmsd remain around 1 Å and become stabilized in the last 10ns of molecular dynamics. 
As concerns protein rmsd values, they are, as expected, bigger than those for the ligands, although remaining 
low. A visualization of the MD movie allows concluding that the movement of the ligands is connected to the 
movement of the binding pocket showing parallel rmsd values,  
 
 
 
3.2 Binding Free Energy Calculations  
 
Reproducing absolute binding free energies is one of the most challenging problems in molecular 
modeling. Although different methodologies have been developed to this end, none of them is able to obtain 
binding free energies without requiring an enormous computational cost, thus preventing their use in standard 
drug-design projects [46,47]. In this work we have adopted the MM-PB/GBSA methodologies because they are 
computationally efficient, not restricted to closely related chemical structures, allow for rigorous total free 
energy decomposition and have been successfully applied in many cases [48-50]. However, it is worth to note 
that neither MM-PBSA nor MM-GBSA reproduce accurately the absolute experimental binding free energies, 
although fortunately, they have been proven to produce good correlations with experimental values [23].  
In order to investigate the stability of the five studied complexes, MM-PBSA and MM-GBSA binding 
free energies (ΔGb), calculated along the whole MD trajectory, were plotted as a function of time. As can be seen 
in Figure S1 (Supporting Information), the obtained plots show some differences. Thus, the 3C4C and 3IDP 
complexes exhibit a very fast convergence of both MM-PBSA and MM-GBSA energies while the 1UWJ and 
3II5 complexes need about 5 ns to converge. Finally, about 10 ns are needed to stabilize the 3Q96 complex, 
which shows big fluctuations at the beginning of its MD trajectory.  
The binding free energy values obtained within the MM-PBSA and MM-GBSA approaches are shown in 
Table 1. As can be seen, although the differences in the experimental ΔGb values are small, both methods are 
able to distinguish the most potent inhibitors from the less potent ones. Moreover, the correlation between 
experimental and theoretical values is very good as we can see from the calculated R2 values: 0.79, 0.85, 0.69, 
and 0.88 for the ΔGGB_total, ΔGPB_total (without entropic contribution), ΔGGB and ΔGPB (with entropic contribution) 
calculations, respectively. We can note that the R2 value decreases for the GB method but slightly increases for 
the PB method when the entropy contribution is included. In any case, the PB approximation produces the best 
correlation. 
The analysis of the different contribution terms to the total binding free energy (Table S1 of Supporting 
Information) allows one to conclude that the major driving forces during the formation of the V600EB-Raf-
inhibitor complexes are the van der Waals and non-polar solvation interactions (ΔGnonpolar,PB/GB + ΔHvdW ). On the 
other hand, although the electrostatic interactions in gas phase positively contribute to the binding, the polar-
solvation effect makes the total electrostatic contribution unfavorable (ΔGpolar,PB/GB + ΔHee). The electrostatic 
contribution in gas phase is especially low for the 3II5 and 3Q96 complexes, probably due to the net charge of 
these ligands. In the case of 3II5, the binding free energy has an important contribution from the gas phase non-
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polar enthalpy (ΔHvdW), which is compensated by a small gas phase polar enthalpy (ΔHee) and a big solvation 
penalty. 
In order to improve our quantitative results, we adapted the recently suggested idea that a single long 
simulation may produce incorrect quantitative results due to inadequate sampling of conformational space, and 
thus multiple short simulations could better explore the conformational space than a single long simulation [51]. 
Consequently, each one of the minimized complexes (see Section 2.3) was subjected to ten 10 ns MD runs. 
Results are presented in Table 2. It can be seen that the use of ten short MD runs significantly increases the 
correlation with experimental data in the case of MM-GBSA (R2=0.69 versus R2=0.86), while the opposite 
happens in the case of MM-PBSA (R2=0.88 versus R2=0.82). In general, binding free energy values obtained 
from the multiple dynamics calculations using only the last 5 ns or the full length (10 ns) simulation time are 
very similar. Only the 3Q96 system, which needs more than 10 ns to be stabilized, presents important differences 
between these two approaches. On the other hand, differences between binding free energies obtained using 
averaged values from multiple MD runs or obtained from one long MD run are not very important, although they 
are case and method dependent. Thus, focusing in the differences between ΔGX and ΔGX mean_10 (where X refers 
to the PB or GB approaches), these are in all cases higher for MM-PBSA than for MM-GBSA. The maximum 
difference is observed for MM-PBSA in the case of the 3Q96 system (32.6%) and the minimum (3.2%) for the 
3II5 one. For MM-GBSA the maximum and minimum differences are obtained for 3Q96 (19.8%) and 3IDP 
(1.1%), respectively.  
Taking these results together, we can conclude that for these systems multiple short molecular dynamics 
runs do not always improve the predicted binding free energies, unlike previous findings pointed out [52]. 
However, if a particular system needs more than 10 ns to achieve energetic stabilization, the methodology should 
be adapted in such a way that these multiple molecular dynamics runs were run for a longer simulation time in 
order to improve molecular sampling or even a case adaptive length, depending on the convergence of each 
studied system, should be used. 
 
3.3 Hydrogen bond analysis 
 
Hydrogen bonds, although being basically electrostatic in nature, have an important contribution to the 
bioactive structures of protein-ligand complexes due to its directionality requirements. The most important 
hydrogen bond interactions found from an analysis of the last 5 ns of the MD of the V600EB-Raf-inhibitor 
complexes are shown in Table 3 and Figure 3. In Figure S2 (Supporting Information), the ligand atoms involved 
in these interactions are schematically represented. 
In all the studied complexes, residue F595 points away from the cavity during the whole trajectory. This 
orientation (DFG-out) is favored by the hydrogen bond network established between the protein and the ligand 
in this part of the cavity. In all cases, the ligand forms a hydrogen bond with the amide nitrogen of D594 (Figure 
3). An additional hydrogen bond is formed between the ligand and the side chain oxygen of E501 in all 
complexes but 3C4C. In this case, the ligand establishes a second interaction with the carbonyl oxygen of D594. 
The lack of interaction with E501 in this complex can be attributed to the loss of planarity produced by the 
presence of a sulfonamide moiety. However, it is important to note that regardless of whether E501 interacts or 
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not with the ligand, the side chain of this residue appears always hydrogen bonded to the amino group of residue 
K483. Also remarkable is the fact that, independently of the size and nature of the linker located at the same 
position that the urea group of Sorafenib (PDB Id. 1UWJ), the interaction of an acceptor atom of the ligand and 
the amide nitrogen of residue D594 is maintained across the series of V600EB-Raf-inhibitor complexes. In the case 
of the 3Q96 complex, the inhibitor forms an additional hydrogen bond with the side chain of D594. This 
hydrogen-bond network may contribute to the stabilization of the DFG-out conformation of V600EB-Raf. 
A second hydrogen bond zone is located around the hinge region (Figure 3). In this region, the 
interaction with residue C532 seems to play a critical role in the potency of these compounds. The three most 
active compounds (3C4C, 3Q96 and 3IDP) are hydrogen bonded to the backbone N atom of residue C532. Thus, 
3C4C uses the N atom of the 7-azaindole ring, 3IDP its purine moiety and 3Q96 its bicycle pyridine lactam 
moiety. Moreover, in the case of 3Q96 and 3IDP, the presence of an additional hydrogen bond involving the 
carbonyl oxygen atom of this cysteine residue improves their potency. Finally, 3C4C also presents a hydrogen 
bond between the NH group of its azaindole ring and the Q530 residue.  
Taken together, these results suggest that the hydrogen bonds established between each ligand and 
D594 and E501 residues, as well as the intramolecular one established between K483 and E501 play a critical 
role in the inhibitory potency of these compounds. Moreover, although interaction of each ligand with residue 
C532 is not needed for activity (see 1UWJ and 3II5), it can significantly improve the inhibitor potency by 
establishing one or two hydrogen bonds. 
 
3.4 Pairwise Binding Free Energy Decomposition  
 
In order to achieve a better understanding of the interactions involved in the binding process, the 
contribution of each V600EB-Raf residue to the total binding free energy of all five complexes was analyzed using 
the MM-GBSA decomposition protocol [45]. Figure 4 shows those residues having a contribution to the total 
binding free energy lower than -1 kcal/mol for at least one of the systems in order to compare the same residues 
in the five analyzed complexes. As in many other kinases, Type II V600EB-Raf inhibitors bind to a long and 
narrow pocket, where they establish numerous protein-ligand contacts. In this scenario, and as can be seen in 
Figure 4, the binding free energy of the different complexes can be expressed as the sum of the contributions of 
many individual residues. 
The protein residues that show the highest contribution to the binding free energy of the complexes are 
precisely those establishing hydrogen bonds with the ligand (Figures 3,4). These residues are: (1) E501, which 
contributes in more than -5 kcal/mol to the formation of the complex. An exception is the 3C4C complex, in 
which there is no hydrogen bond between this residue and the ligand; (2) D594, which in all cases appears 
hydrogen bonded to the ligand. The contribution of this residue to the binding free energy is larger in the case of 
3C4C and 3Q96 due to the formation of an additional hydrogen bond with the ligand; (3) C532, whose 
contribution increases in those complexes where it forms hydrogen bond interactions with the ligand (i.e., 3C4C, 
3Q96 and 3IDP) and; (4) I463 and Q530, whose binding energy contribution for 3II5 and 3C4C is due to the 
formation of a hydrogen bond with the ligand. 
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To gain insight into the structural requirements that a Type II inhibitor must fulfil to achieve optimal 
interactions with the V600EB-Raf protein, and therefore, to improve its potency, we will focus our discussion on 
the interactions identified in the 3IDP complex, which shows the strongest binding energy. These interactions 
will be systematically compared in a further step with those found in the other complexes studied in the present 
work. 
  
Complex 3IDP. The interactions found relevant in 3IDP can be summarized as follows: (1) the purine 
ring, which forms a bidentate hydrogen bond with the amide nitrogen and carbonyl oxygen of C532 (Figure 3), 
interacts with F583 and W531 through a π-π parallel stacking (Figure 5a); (2) the pyridine ring interacts with 
I463 and V471 at the ATP-binding pocket and with E600, F595, V471 and K483 (Figure 5b) but not with  
residue L597 as in the crystallographic complex. The loss of this interaction is due to the different orientation 
adopted by this leucine residue during the MD; (3) the N-substituted ring of the isoquinoline moiety forms a 
hydrogen bond with the amide nitrogen of D594, interacts with residues L514 and T529 and forms a π–π 
perpendicular stacking with F595 (Figure 5b). The methyl substituted ring of this moiety also interacts with 
T529 and is involved in a π-cation interaction with K483 while the methyl group of the isoquinoline moiety 
establishes hydrophobic contacts with A481 and T529; (4) the NH group that links the isoquinoline group with 
the terminal 4-chlorophenyl ring forms a hydrogen bond with the O side chain of D501 and (5) 4-chlorophenyl 
ring mainly interacts with L505, I513 and V504. Finally, it is worth to mention that the 3IDP crystal structure 
shows a water molecule involved in a hydrogen bridge between the ligand, D594 and K483. However, any 
attempt to keep this water molecule in its crystal position failed in the initial minimization steps.  
 
Complex 1UWJ vs. 3IDP. Figure S3 (Supporting information) shows the ligands 3IDP and 1UWJ 
superimposed in the binding site of V600EB-Raf and Figure 3 shows their interactions with the binding site 
residues. As can be seen, the most important structural differences between them are the replacement of the 
purine and isoquinoline moieties of 3IDP by a single aromatic ring in 1UWJ, and the elimination of the pyridine 
ring linking both moieties with the subsequent shortening of this linker. These modifications result in a drop of 
the contribution of residues K483, T529, W531 and C532 (Figure S4). In the 1UWJ complex, K483 and W531 
are not involved in π-stacking interactions with the ligand. Furthermore, C532 does not form any direct 
intermolecular hydrogen bond, although one between its amide nitrogen and the N atom of the pyridine ring has 
been observed in the crystallographic structure [3]. This interaction has been replaced in our MD simulation by a 
water mediated hydrogen bond (Figure S5). On the other hand, the methyl amide moiety located in this part of 
the cavity increases the contribution of residue I463 to the binding of 1UWJ. 
The orientation adopted by residue E501 in the 1UWJ complex, facilitated by the bifurcated hydrogen 
bond that is formed between its O side chain and the two N atoms of the urea linker, maximizes its interaction 
with the ligand and, therefore, its contribution to complex formation. Similarly, the different orientation adopted 
by the 4-chloro-3-trifluorobenzyl moiety of 1UWJ compared with the corresponding one of 3IDP increases the 
contribution of residues H574 and D594. 
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Complex 3II5 vs. 3IDP. As in the case of 1UWJ, the structural differences between these two ligands 
can be used to explain the different binding energies of their complexes with V600EB-Raf. The non-substituted 
aromatic ring of 3II5 is placed in the same region as the isoquinoline moiety of 3IDP, but with a slightly 
different orientation (Figure S3, Supporting Information). This fact, together with the presence of a single 
aromatic ring instead of a bicyclic system, hampers the π- stacking interactions between the ligand isoquinoline 
moiety and residues K483 and F595 seen in 3IDP. The close residues A481, T529 and G593 present an 
important change in their contributions to the binding energy and the structural changes in the binding site also 
affect D594, which adopts a conformation that maximizes its interaction with the ligand in the 3II5 complex. 
The pyrazolo[1,5-a]pyrimidine group is placed and oriented similarly to the pyridine group of 3IDP (Figure S3). 
However, its bigger size favors the interaction with the nearby residues I463, V471, L597 and E600, increasing 
their binding free energy contribution (Figure S4). The 4-Ph-CH2–NH(CH3)2+ group of 3II5 is placed in a region 
of the cavity unoccupied by 3IDP, thus increasing the contribution of V471, L597, E600 and S465 (Figure S4, 
Supporting Information). Moreover, the presence of a positively charged group in this region of the binding site 
favors the formation of a hydrogen bond with the carbonyl oxygen of I463, which has not been observed in the 
crystallographic structure [36]. However, by comparison with 3IDP, the orientation adopted by this 4-Ph-CH2–
NH(CH3)2+ group in 3II5 implies a drop in the contribution of residues A481, W531 and C532 to the stability of 
the 3II5 complex. Finally, the orientation adopted by the trifluoromethylphenyl group is very similar to that 
observed for the corresponding ring in the 1UWJ complex, which translates into a drop in the contribution of 
I513 and L514 and an increase of H574 and D576. 
 
Complex 3C4C vs. 3IDP. The binding of 3C4C to V600EB-Raf shows the following differences as 
compared with 3IDP: (1) the orientation adopted by the azaindole group, placed in the same region as the purine 
ring of 3IDP, allows the formation of two hydrogen bonds between the N1 and N7 atoms and residues Q530 and 
C532, respectively (Figure 3) [34]. The ability of 3C4C to form a hydrogen bond with Q530, a characteristic 
unique to this compound, accounts for the higher contribution of this residue to the stability of the complex; (2) 
the presence of a chlorine atom in position 5 of the azaindole moiety reinforces the interaction of the ligand with 
residue I463, increasing its binding free energy contribution; (3) the smaller size and slightly different 
orientation of the difluorophenyl ring of 3C4C in comparison to the isoquinoline ring of 3IDP (Figure S3), 
decreases the contribution of residues A481,K483, T529 and F595 (Figure S4); (4) the carbonyl oxygen and 
amide nitrogen of D594 are hydrogen bonded to the N and O atoms of sulfonamide, increasing its contribution to 
the binding free energy of the complex; (5) in contrast to the 3IDP complex, residue E501 is not hydrogen 
bonded to the ligand, making its contribution lower; (6) the hydrophobic propyl group cannot achieve the same 
interactions as the aromatic chlorophenyl moiety of 3IDP with residues I513, I592 and G593, hence decreasing 
their contribution; (7) it can be observed a decrease in the contribution of E600 due to the lack of interaction 
with the pyridine moiety of 3IDP, absent in the 3C4C ligand. 
 
Complex 3IDP vs. 3Q96. Although 3IDP and 3Q96 have similar activity, there are many structural 
differences between them. First, the pyridine cycle of 3IDP is not present in 3Q96, producing a decrease in the 
contributions of residues V471, E600 and F595. The methyl group of the isoquinoline moiety is also missing in 
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3Q96, causing now a drop in the contribution of A481 and K483. Moreover, although the isoquinoline moiety of 
3IDP and the tetrahydronaphthalene group of 3Q96 have the same size and are placed in the same region within 
the binding site, their different orientation modifies the contribution of the surrounding residues to the formation 
of the respective complexes. Thus, L514 and T529 contribute less in the 3Q96 complex (Figure S4). Similarly, 
the different orientation adopted by the trifluoromethylphenyl distal ring of 3Q96, as compared with the 
equivalent chlorophenyl  group in 3IDP, diminishes the contribution of G593 and I513. This is not the case for 
the indole and the bicyclic pyridine lactam in the ATP-binding region of 3IDP and 3Q96, respectively, which 
show a similar interaction pattern (Figure S3). One of the most relevant features of the 3Q96 complex is that the 
methylamino group of the fluorinated ring occupies an additional region of the binding site, increasing the 
contribution of residues H574 and D576. Also remarkable is the enhanced contribution of residues E501 and 
D594 in the 3Q96 complex as compared to 3IDP. All the other contributions, being in their vast majority of 
hydrophobic character, show the opposite trend. Thus, it can be suggested that in order to obtain the directional 
interactions of these charged residues and to establish good hydrogen bonds with the 3Q96 ligand, a global 
hydrophobic destabilization is needed. 
 
3.5 Structural requirements for V600EB-Raf inhibition 
 
The results obtained in the present work show that the formation of a hydrogen bond network involving 
the ligand and protein residues D594, E501 and K483 plays a critical role in the stabilization of the DFG-out 
conformation of V600EB-Raf by inhibitor binding. In all the complexes studied, the ligand forms a hydrogen bond 
with the amide nitrogen of D594. Although most of the inhibitors studied here are also hydrogen bonded to the 
side chain oxygen of E501, this interaction seems not to be critical for activity. Thus, the 3C4C ligand does not 
interact with this glutamic, being however an active inhibitor. Yet, regardless of whether E501 interacts or not 
with the ligand, this residue appears always hydrogen bonded to K483. On the other hand, the complexes of the 
three most active compounds show a hydrogen bond with C532. Although this interaction does not seem to be 
essential for activity (1UWJ and 3II5 have activities in the nM range without exhibiting this interaction), its 
presence leads to an increase of activity.  
Also hydrophobic interactions have a significant role in the inhibition of V600EB-Raf. Our results appear 
to indicate that the ligands have to display at least three features: (1) an hydrophobic (or aromatic) group, located 
in the zone occupied by the 4-chlorophenyl moiety of 3IDP, which interacts with V504 and L505; (2) an 
hydrophobic group, preferably aromatic, to allow a π-cation stacking interaction with K483, which would also 
interact with residues V471, A481, L514, T529 and F595 and, (3) an aromatic group, placed near the pyridine 
moiety of 3IDP and close to the last mentioned hydrophobic group, interacting with I463 and F583. Moreover, 
the presence of an additional hydrophobic feature, located nearby the 4-chlorophenyl moiety of 3IDP, able to 
interact with L567 and I572, could increase the inhibitory potency of the compounds. 
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4. CONCLUSIONS 
 
In this work, the energetics and structural keys of the binding of five different inhibitors to the 
oncogenic protein V600EB-Raf in its DFG-out conformation have been studied using MD and free energy 
calculations. The results obtained show that the binding free energy of these complexes is due to the individual 
contribution of many residues distributed throughout the binding site of the protein. Among them, those residues 
involved in the formation of hydrogen bonds show the highest contribution. Specifically, residues K483, D594 
and E501 have been found to play a critical role in the inhibition of V600EB-Raf. In all the cases, D594 is 
hydrogen bonded to the ligand, whereas E501 is intramolecularly bonded to K483. The interaction of this 
glutamic residue with the ligand, observed in most of the studied complexes, seems not to be critical for activity. 
In fact, 3C4C lacks this interaction and is still highly active. It has been found for residue C532 that its 
interaction through hydrogen bond with the ligand leads to an increase in the activity of the compound. On the 
other hand, three different hydrophobic features of the ligands have been found critical for activity. These 
features, distributed along the cavity, are located near the chlorophenyl, isoquinoline and pyridine moieties of the 
3IDP ligand. For these last two, the incorporation of an aromatic moiety favors the π-stacking interaction with 
residues K483 and F595. The incorporation of a fourth hydrophobic interaction accounting for the 4-chloro 
substituent of 3IDP is expected to increase the inhibitory potency of these compounds. 
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Figure 1. Structures of the five B-Raf inhibitors studied in this work. 
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Figure 2. The RMSD values as a function of the simulation time of the C protein atoms, ligand atoms and 
binding pocket, the latter defined by those protein residues within 4.5 Å of any ligand atom, for: (a) 1UWJ, (b) 
3II5, (c) 3C4C, (d) 3Q96 and  (e) 3IDP (f) RMSF of each residue of the protein for all five complexes obtained 
from 30 ns of molecular dynamics simulation.  
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Figure 3. Structure comparison between representative snapshots from the last ns MD of: (a) 1UWJ, (b) 3II5, (c) 
3C4C, (d) 3Q96, and (e) 3IDP complexes at the active site of B-Raf with its corresponding inhibitor. 
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Figure 4. Contribution of key residues of B-Raf to the total binding free energy for the systems: 1UWJ, 3II5, 
3C4C, 3Q96, and 3IDP. 
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Figure 5. 3IDP/B-Raf interaction pattern. a) and b) are related by a rotation of 180o around the perpendicular 
axis.  
a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Current Computer-Aided Drug Design  Coronel et al. 
25 
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Table 1. Binding free energies (kcal/mol) and their different contributions for the studied Ligand/B-Raf 
complexes averaged over the last 5 ns of molecular dynamics. In this Table, ΔHvdW and ΔHee are the van der 
Waals and electrostatic molecular mechanics energies; ΔGpolar_X and ΔGnonpolar_X represent the electrostatic and 
nonpolar contributions to the solvation free energy respectively and ΔGX = ΔGX_total − TΔS, with X being the GB 
or PB method. Experimental IC50 values were obtained from references 3,20-23 for 1UWJ, 3C4C, 3IDP, 3II5, 
3Q96 respectively.  
 
System 1UWJ 3II5 3C4C 3Q96 3IDP 
ΔHvdW -56.96 -64.20 -47.95 -65.38 -70.33 
ΔHee -30.66 -11.92 -34.89 -4.18 -47.45 
ΔGpolar_PB 52.17 45.32 47.87 26.26 65.50 
ΔGnonpolar_PB -6.45 -7.15 -5.69 -7.64 -6.61 
ΔGpolar_GB 43.64 31.07 39.59 16.71 52.10 
ΔGnonpolar_GB -7.79 -8.23 -6.34 -8.46 -7.07 
ΔGPB_total -41.89 -37.95 -40.66 -50.94 -58.89 
ΔGGB_total -51.77 -53.29 -49.59 -61.31 -72.74 
-TΔS 21.06 17.13 18.88 23.59 24.52 
ΔGPB -20.83 -20.82 -21.78 -27.35 -34.37 
ΔGGB -30.71 -36.16 -30.71 -37.72 -48.22 
IC50 (nM) 38 24 13 2.9 1.6 
Gexp -10.12 -10.39 -10.75 -11.64 -11.99 
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Table 2.  Binding free energies ( kcal/mol) , including the entropic contribution, calculated with the MM-PBSA 
and MM-GBSA approaches using the last 5n of the full molecular dynamics run (ΔGX),  the mean of the total 
length of ten 10ns molecular dynamics (ΔGX_mean_10) or the mean of the last 5ns of the ten 10ns molecular 
dynamics (ΔGX_mean_5) for the different Ligand/B-Raf complexes, being X equal to PB or GB methods.  
 
System 1UWJ 3II5 3C4C 3Q96 3IDP R
2 
ΔGPB -20.83 -20.82 -21.78 -27.35 -34.37 0.88 
ΔGPB_mean_5 -26,97 -20.10 -24.00 -33.43 -41.98 0.76 
ΔGPB_mean_10 -27.16 -20.16 -25.76 -36.28 -42.78 0.82 
ΔGGB -30.71 -36.16 -30.71 -37.72 -48.22 0.69 
ΔGGB_mean_5 -32.72 -32.57 -29.54 -41.91 -48.08 0.81 
ΔGGB_mean_10 -32.50 -31.83 -30.08 -45.21 -47.69 0.86 
ΔGexp -10.12 -10.39 -10.75 -11.64 -11.99  
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Table 3.  Hydrogen bonds with an occupancy greater than 30% obtained from the last 5 ns of the MD trajectory. 
Average distances and angles are also shown (standard deviation in parenthesis) 
 System Donor Acceptor Occupancy(%) Distance(Å) Angle (o) 
1UWJ D594 HN ligand O15 100.0 2.91 (0.13) 24.0 (10.5) 
 ligand HN14 E501 OE2 100.0 2.91 (0.15) 32.2 (9.1) 
 ligand HN12 E501 OE2 100.0 2.82 (0.11) 23.7(8.5) 
 K483 HN  I527   O 100.0 3.00 (0.15) 24.5 (10.8) 
 K483 HNZ1 D594 O 50.4 2.80 (0.10) 22.4 (11.7) 
 K483 HNZ3 E501 OE2 50.0 2.85 (0.13) 25.1 (13.1) 
 K483 HNZ3 E501 OE1 42.8 3.04 (0.17 39.2 (12.2) 
3II5 D594HN ligand O1 82.4 3.03 (0.15) 21.3 (11.1) 
 ligand H55 E501 OE1 86.0 3.01 (0.18) 25.6 (8.5) 
 ligand HN1 I463 O 59.6 2.92 (0.16) 24.5 (13.3) 
 K483 HNZ2 E501 OE2 68.4 2.85 (0.13) 26.0 (10.4) 
 K483 HNZ1 E501 OE1 60.8 2.90 (0.15) 43.2 (9.8) 
 K483 HNZ2 E501 OE1 31.2 2.87 (0.12) 24.3 (12.2) 
3C4C ligand HN7 Q530  O 100.0 2.84 (0.11) 18.33 (9.8) 
 D594 HN ligand O23 99.6 2.91 (0.14) 21.0 (10.7) 
 C532 HN ligand N4 96.0 3.07 (0.15) 21.0 (11.5) 
 ligand HN21 D594 O 94.0 3.02 (0.19) 22.5 (9.7) 
 K483 HNZ1 E501 OE1 38.4 2.75 (0.09) 21.7 (10.1) 
 K483 HNZ2 E501 OE1 33.2 2.75 (0.08) 20.8 (10.8) 
3Q96 ligand HN24 E501 OE1 100.0 2.90 (0.14) 14.11 (7.2) 
 D594 HN ligand O23 97.6 3.00 (0.17) 23.53 (11.7) 
 C532 HN ligand N2 94.8 3.04 (0.14) 29.42 (13.8) 
 ligand HN7 C532 O 92.0 3.10 (0.19) 17.0 (10.7) 
 ligand HN33 D594 OD1 61.2 2.78 (0.11) 17.7 (9.1) 
 K483 HNZ1 E501 OE2 45.6 2.81 (0.11) 24.9 (13.6) 
 K483 HNZ2 E501 OE2 40.0 2.83 (0.13) 22.7 (11.9) 
 K483 HNZ1 E501 OE1 34.0 3.07 (0.22) 40.9 (12.4) 
3IDP ligand HN25 E501 OE2 99.2 2.88 (0.13) 13.7 (7.8) 
 C532 HN ligand N6 96.8 2.99 (0.12) 25.7 (14.0) 
 ligand HN33 C532 O 94.4 2.99 (0.17) 25.7 (12.8) 
 D594 HN ligand N23 79.6 2.98 (0.11) 41.1 (12.4) 
 K483 HNZ2 D594 O 34.8 2.78 (0.10) 24.7 (12.6) 
 K483 HNZ1 E501 OE2 34.0 2.77 (0.10) 27.8 (10.7) 
 
